Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

5,263JPY
10:29pm EDT
Change (% chg)

¥68 (+1.31%)
Prev Close
¥5,195
Open
¥5,250
Day's High
¥5,303
Day's Low
¥5,237
Volume
999,600
Avg. Vol
2,154,437
52-wk High
¥5,527
52-wk Low
¥4,098

4502.T

Chart for 4502.T

About

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Ethical Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, anticancer drugs, drugs for central neurological diseases,... (more)

Overall

Beta: 0.71
Market Cap(Mil.): ¥4,159,181.00
Shares Outstanding(Mil.): 790.42
Dividend: 90.00
Yield (%): 3.42

Financials

  4502.T Industry Sector
P/E (TTM): 31.26 29.17 29.94
EPS (TTM): 168.35 -- --
ROI: 4.33 13.48 13.01
ROE: 6.48 14.39 14.16

BRIEF-Takeda Pharmaceutical forms drug development company with two partners - Nikkei

* Takeda pharmaceutical formed 10 billion yen ($87.2 million) drug development company with two partners

Mar 14 2017

BRIEF-R&I removes Takeda Pharmaceutical from rating monitor and downgrades rating to "AA-" – R&I

* Rating and Investment Information, Inc. (R&I) removed the co from rating monitor - R&I

Mar 01 2017

Longer survival seen with Amgen's Kyprolis vs Velcade in myeloma study

Patients with relapsed multiple myeloma treated with Amgen Inc's Kyprolis lived more than seven months longer than those who received Takeda Pharmaceutical Co's Velcade, according to data from a late-stage study released by Amgen on Tuesday.

Feb 28 2017

Longer survival seen with Amgen's Kyprolis vs Velcade in myeloma study

Feb 28 Patients with relapsed multiple myeloma treated with Amgen Inc's Kyprolis lived more than seven months longer than those who received Takeda Pharmaceutical Co's Velcade, according to data from a late-stage study released by Amgen on Tuesday.

Feb 28 2017

BRIEF-Takeda Pharmaceutical to transfer consumer healthcare business to wholly owned unit

* Says the co plans to transfer domestic consumer healthcare business to its wholly owned unit, a Tokyo-based medical supplies firm

Feb 20 2017

BRIEF-Takeda Pharmaceutical completes acquisition of ARIAD Pharmaceuticals

* Says co completes full acquisition of ARIAD Pharmaceuticals Inc on Feb. 16(U.S. local time), at $24.00 per share

Feb 17 2017

BRIEF-Takeda Pharmaceutical says PRA Health Sciences and Takeda Partnership Expands to Japan

* Says PRA Health Sciences Inc and Takeda Pharmaceutical Company Limited have agreed to a new partnership to expand their global relationship initially disclosed in September 2016 to include Japan

Feb 15 2017

D.C. Circuit refuses to revive Takeda appeal to block rival gout drug

A federal appeals court has refused to revive Takeda Pharmaceutical Co and its hedge fund investor Elliott Associates' bid to block Hikma Pharmaceuticals PLC from selling its gout drug Mitigare.

Feb 13 2017

Judge revives antitrust claims against Takeda over Actos

A federal appeals court on Wednesday revived claims by health plans accusing Takeda Pharmaceuticals of delaying generic versions of its blockbuster diabetes drug Actos by misrepresenting patents it had on the drug.

Feb 09 2017

Takeda urges Federal Circuit to revive Velcade patent

A lawyer for Japanese drugmaker Takeda Pharmaceuticals Co on Monday urged a federal appeals court to revive a patent on its top-selling cancer drug Velcade, which faces generic competition later this year.

Feb 08 2017

More From Around the Web

Earnings vs. Estimates